| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Co-chief Scientific Officer | EVP Research
1 company
Murphy Andrew J serves as a Co-chief Scientific Officer at REGN. Across recent SEC filings that breaks down to 0 buys and 236 sells. Those positions are worth an estimated $37.4M at current prices.
Historically, Murphy Andrew J's trades have earned a middling insider score of 54/100 across 10 rated trades. Over a 12-month horizon, 30.0% of those trades were profitable, with an average 12-month return of -0.2%.
The biggest single holding is REGN (~$37.4M) as Co-chief Scientific Officer. The recent filings there lean toward selling, a net 86,863 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | REGN Regeneron Pharmaceuticals, Inc. | Co-chief Scientific Officer | Sale+OE | 4,147 | $772.70 | $3,204,375.76 | -8.0% | - | - | |
| Aug 14, 2024 | REGN Regeneron Pharmaceuticals, Inc. | EVP Research | Sale+OE | 6,363 | $1,153.15 | $7,337,504.87 | -11.6% | -29.0% | -51.1% | |
| Mar 14, 2024 | REGN Regeneron Pharmaceuticals, Inc. | EVP Research | Sale+OE | 6,037 | $955.16 | $5,766,316.52 | -11.1% | +7.2% | -30.5% | |
| Dec 5, 2023 | REGN Regeneron Pharmaceuticals, Inc. | EVP Research | Sale+OE | 6,536 | $817.44 | $5,342,787.40 | -9.9% | +18.3% | -8.1% | |
| Nov 14, 2023 | REGN Regeneron Pharmaceuticals, Inc. | EVP Research | Sale+OE | 6,492 | $799.17 | $5,188,213.10 | -9.8% | +19.3% | +1.3% | |
| Nov 15, 2022 | REGN Regeneron Pharmaceuticals, Inc. | EVP Research | Sale+OE | 3,829 | $726.76 | $2,782,762.77 | -6.3% | +4.8% | +8.7% | |
| Aug 16, 2022 | REGN Regeneron Pharmaceuticals, Inc. | EVP Research | Sale+OE | 3,513 | $645.49 | $2,267,600.12 | -5.7% | +14.4% | +22.9% | |
| May 17, 2022 | REGN Regeneron Pharmaceuticals, Inc. | EVP Research | Sale+OE | 3,543 | $663.68 | $2,351,411.44 | -5.7% | -3.6% | +12.3% | |
| Feb 15, 2022 | REGN Regeneron Pharmaceuticals, Inc. | EVP Research | Sale+OE | 3,540 | $629.34 | $2,227,850.52 | -5.7% | +3.9% | +19.4% | |
| Dec 10, 2021 | REGN Regeneron Pharmaceuticals, Inc. | EVP Research | Sale+OE | 7,122 | $666.27 | $4,745,202.38 | -10.7% | -5.8% | +12.0% |